Literature DB >> 32718857

Lipoprotein(a) concentration, genetic variants, apo(a) isoform size, and cellular cholesterol efflux in patients with elevated Lp(a) and coronary heart disease submitted or not to lipoprotein apheresis: An Italian case-control multicenter study on Lp(a).

Claudia Stefanutti1, Livia Pisciotta2, Elda Favari3, Serafina Di Giacomo4, Federica Vacondio3, Maria Grazia Zenti5, Claudia Morozzi4, Daniele Berretti6, Dario Mesce4, Marco Vitale4, Andrea Pasta7, Annalisa Ronca8, Anna Garuti7, Matteo Manfredini9, Eduardo Anglés-Cano10, Santica Marija Marcovina11, Gerald Francis Watts12.   

Abstract

BACKGROUND: Coronary artery disease (CAD) risk is greater with higher plasma lipoprotein(a)[Lp(a)] concentrations or smaller apoisoform size and putatively with increased cellular cholesterol loading capacity (CLC). The relationship between Lp(a) and CLC is not known. Information on Lp(a) polymorphisms in Italian patients is lacking.
OBJECTIVE: The objective of this study was to determine relationships between Lp(a) and CLC, the impact of lipoprotein apheresis (LA), and describe the genetic profile of Lp(a).
METHODS: We conducted a multicenter, observational study in Italian patients with hyperLp(a) and premature CAD with (n = 18)/without (n = 16) LA in which blood samples were analyzed for Lp(a) parameter and CLC. Genetic profiling of LPA was conducted in patient receiving LA.
RESULTS: Mean macrophage CLC of the pre-LA serum was significantly higher than that of normolipidemic controls (19.7 ± 0.9 μg/mg vs 16.01 ± 0.98 μg/mg of protein, respectively). After LA, serum macrophage CLC was markedly lower relative to preapheresis (16.1 ± 0.8 μg/mg protein; P = .003) and comparable with CLC of the normolipidemic serum. LA did not significantly affect average apo(a) isoform size distribution. No anthropometric or lipid parameters studied were related to serum CLC, but there was a relationship between CLC and the Lp(a) plasma concentration (P = .035). DNA analysis revealed a range of common genetic variants. Two rare, new variants were identified: LPA exon 21, c.3269C>G, p.Pro1090Arg, and rs41259144 p.Arg990Gln, c.2969G>A
CONCLUSIONS: LA reduces serum Lp(a) and also reduces macrophage CLC. Novel genetic variants of the LPA gene were identified, and geographic variations were noted. The complexity of these polymorphisms means that genetic assessment is not a predictor of CAD risk in hyperLp(a).
Copyright © 2020. Published by Elsevier Inc.

Entities:  

Keywords:  Cholesterol loading capacity; Genetic polymorphisms; Genetics; HyperLp(a); Lipoprotein apheresis; Particle size

Mesh:

Substances:

Year:  2020        PMID: 32718857     DOI: 10.1016/j.jacl.2020.05.002

Source DB:  PubMed          Journal:  J Clin Lipidol        ISSN: 1876-4789            Impact factor:   4.766


  4 in total

Review 1.  Lipoprotein(a) beyond the kringle IV repeat polymorphism: The complexity of genetic variation in the LPA gene.

Authors:  Stefan Coassin; Florian Kronenberg
Journal:  Atherosclerosis       Date:  2022-05       Impact factor: 6.847

2.  Development of an LC-MS/MS Proposed Candidate Reference Method for the Standardization of Analytical Methods to Measure Lipoprotein(a).

Authors:  Santica M Marcovina; Noémie Clouet-Foraison; Marlys L Koschinsky; Mark S Lowenthal; Allen Orquillas; Michael B Boffa; Andrew N Hoofnagle; Tomáš Vaisar
Journal:  Clin Chem       Date:  2021-03-01       Impact factor: 12.167

3.  Elevated lipoprotein(a) and genetic polymorphisms in the LPA gene may predict cardiovascular events.

Authors:  Jun-Xu Gu; Juan Huang; Shan-Shan Li; Li-Hua Zhou; Ming Yang; Yang Li; Ai-Min Zhang; Yue Yin; Na Zhang; Mei Jia; Ming Su
Journal:  Sci Rep       Date:  2022-03-04       Impact factor: 4.379

4.  Serum cholesterol loading capacity on macrophages is linked to coronary atherosclerosis and cardiovascular event risk in rheumatoid arthritis.

Authors:  George Athanasios Karpouzas; Bianca Papotti; Sarah Ormseth; Marcella Palumbo; Elizabeth Hernandez; Maria Pia Adorni; Francesca Zimetti; Matthew Budoff; Nicoletta Ronda
Journal:  RMD Open       Date:  2022-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.